Member Info for undervaluedtoday

2p+ this week mega buying just the tip of the iceberg 10-15p genuine value

RERATING slowly as the market starts to catch up with how UNDERVALUED we are , a blue sky 🩵🌃 stock.

Was always going to happen 10-15p easy

BOOM boom

500k buyer loading

Buy

CLBX.L

Cellbxhealth PLC

Current price1.0990 1.2610

Quote price1.29

Order typeFixed price quote

Quantity1000000

Investment

Commission

£0.00

PTMLevy

£1.50

Consideration

£12,900.00

Total cost£12,901.50

PREMIUM needed for

buy

CLBX.L

Cellbxhealth PLC

Current price 1.0990 1.2610

Quote price 1.2591

Order typeF ixed price quote

Quantity750000

Investment

Commission

£0.00

Consideration

£9,443.25

Total cost £9,443.25

CelLBxHealth is actively finalizing a Master Services Agreement with a top-ten global pharmaceutical company for drug discovery and development. While the company has not officially named the counterparty for this specific agreement, the arrangement is poised to bring broader, large-scale commercial validation to the Parsortix platform for clinical laboratory applications.

CelLBxHealth (formerly ANGLE plc) and AstraZeneca currently have no definitive monetary valuation assigned to a finalized Master Services Agreement (MSA), as the two entities are in the final stages of negotiating this overarching framework.However, prior development and validation contracts successfully completed between the two companies provide direct insights into the financial scope of their assay work

Just tried for Nuformix PLC

Current price0.1700 0.1806

Quote price0.2232

Order typeFixed price quote

Quantity25000000

Investment

Commission

£0.00

SDRT

£279.00

PTMLevy

£1.50

Consideration

£55,800.00

Total cost£56,080.50

Gaining traction

As buying continues

No brainer

A long way north yet

Getting busy

CelLBxHealth plc (formerly ANGLE plc) has recently secured two major clinical research collaborations in early 2026 to validate and expand the use of its proprietary Parsortix circulating tumour cell (CTC) liquid biopsy platform. These partnerships focus on evaluating non-invasive, blood-based cancer diagnostics to improve patient monitoring and guide targeted therapies.

1. AdventHealth Collaboration (May 2026)

CelLBxHealth partnered with the US healthcare network AdventHealth to deploy the Parsortix platform across two multi-centre clinical trials.

PharmaTimes

Scope: Evaluates CTC-based monitoring for colon, gastrointestinal, and lung cancers.

Objective: Validates blood analysis as a correlative endpoint to track how tumours evolve during treatment.

Impact: Utilises AdventHealth's extensive US network to transition advanced cancer monitoring from hospital-based biopsies to accessible community care.

2. The Royal Marsden NHS Foundation Trust Collaboration (April 2026)

The company launched a joint translational clinical study with The Royal Marsden in the UK.

Scope: A prospective study involving 200 patients with advanced non-small cell lung cancer (NSCLC).

Objective: Targets the 10–15% of patients whose standard circulating tumour DNA (ctDNA) tests return uninformative results.

Impact: Uses CTC-derived DNA to reveal missing, actionable genetic mutations, helping patients qualify for targeted therapies they otherwise would miss. Results are anticipated by the end of 2026.

1.5m for starters

Strong Buy

CAVENDISH 4P+ TARGET CelLBxHealth strategic deal...

Cavendish retains its corporate designation and 4p target price, implying upside of more than 350% from current levels.

https://uk.finance.yahoo.com/news/cellbxhealth-shares-jump-17-strategic-085300145.html

Trinity Delta view: Cellbxhealth strategy centres on growing its Pharma Services as it seeks to widen commercial adoption of its proprietary Parsortix technology for CTC capture and subsequent downstream analysis. The marketing focus shifted a year ago towards the better-resourced large pharma customers where, despite more complex selling cycles, there is the potential to drive significant mid- and longer-term revenues. An analogous approach is addressing medtech diagnostics companies to support development of new assays and/or companion diagnostics. There is increasing clinical acceptance that CTC-driven diagnostics can provide complementary actionable information to current liquid biopsy methods, such as ctDNA, including invaluable additional insights that such methods alone cannot, our forecasts and valuation is £118m, or 37p per share.

The 3 analysts offering 12 month price targets for Cellbxhealth PLC have a median target of 17.00, with a high estimate of 30.00 and a low estimate of 4.00. The median estimate represents a 1,689.47% increase from the last price of 0.95.

https://markets.investorschronicle.co.uk/data/equities/tearsheet/forecasts?s=CLBX:LSE

Based on analyst projections, Cellbxhealth (CLBX) has a 12-month average price target ranging between 7.00p and 17.00p. The consensus rating is a "Strong Buy", with forecasts suggesting a potential upside of over 566% to 1,600% from recent trading prices, which have fluctuated around 0.90p–1.05p.

Key Analyst Forecast Details:

Average Target Price: 7.00p (based on 2 analysts) to 17.00p (based on 3 analysts).

High Estimate: Up to 30.00p.

Low Estimate: 4.00p.

Consensus Rating: Strong Buy.

Recent Share Price: 0.90p–1.05p.

Analysts have set a high price target based on projected company growth, although the stock has significantly underperformed, trading near the bottom of its 52-week range and far below its 200-day moving average.

Other Insights:

Growth Forecasts: The company is forecast to grow revenue by 45.1% per annum, according to data from Simply Wall St.

🚕🚕